• Earlier this month, Compass Pathways plc announced it is working with the U.S. Department of Veterans Affairs on PIVOT, a multi-site randomized controlled trial evaluating COMP360 psilocybin for treatment-resistant depression in veterans, including those with PTSD, while also agreeing to present at Stifel’s 2026 Biotech Summer Summit.
• This collaboration with the VA gives COMP360 exposure in a high-need veteran population and may help build clinical and operational know-how around delivering psilocybin-assisted therapy at scale.
• We’ll now examine how this VA-backed PIVOT trial, focused on veterans with treatment-resistant depression and PTSD, could influence COMPASS Pathways’ investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

COMPASS Pathways Investment Narrative Recap

To own COMPASS Pathways, you need to believe COMP360 psilocybin can secure approval in treatment resistant depression and build a scalable care model despite ongoing losses and dilution risk. The VA backed PIVOT trial broadens COMP360’s data set in a high need veteran group, but the near term catalyst remains the FDA review of the TRD NDA, while the biggest risk is still any safety or efficacy issue that complicates approval or labeling.

The VA collaboration stands out among recent announcements because it directly reinforces COMP360’s clinical story in TRD and PTSD, where trial outcomes and regulatory decisions are central to the thesis. By contrast, the universal shelf registration filed on 5 August 2026 highlights the continuing financing overhang, as a larger cash burn and growing net losses in Q2 2026 increase the possibility of further equity or debt issuance.

Yet while the PIVOT trial may strengthen the clinical story, the increased net loss and financing flexibility also raise the possibility that investors should be aware of...

COMPASS Pathways’ narrative projects $284.9 million revenue and $53.9 million earnings by 2029. This implies an earnings increase of about $246 million from -$192.4 million today.

Uncover how COMPASS Pathways' forecasts yield a $24.47 fair value, a 72% upside to its current price.

Exploring Other Perspectives

Before this VA news, the most pessimistic analysts were only looking for about US$72.0 million of revenue and US$12.9 million of earnings by 2029, so if you worry about restrictive labels and cautious early use of COMP360 in TRD and PTSD, their view offers a useful contrast to more optimistic expectations.

Explore 4 other fair value estimates on COMPASS Pathways - why the stock might be worth just $23.75!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your COMPASS Pathways research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free COMPASS Pathways research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate COMPASS Pathways' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
• Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The future of work is here. Discover the 39 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.